Topcon expands AI portfolio with Intelligent Retinal Imaging Systems acquisition

News
Article

The IRIS is a cloud-based model that supports artificial intelligence-assisted diabetic retinopathy screening

Logos for Topcon Healthcare (left, black and purple) and Intelligent Retinal Imaging Systems (IRIS, right, blue and green). Concept image for diabetic eye disease retina screening company merger. Image courtesy of Topcon Healthcare.

Image courtesy of Topcon Healthcare.

Topcon Healthcare, Inc. announced it has acquired cloud-based retinal screening technology company Intelligent Retinal Imaging Systems (IRIS), both US-based companies. In a press release, Topcon expressed intention to integrate IRIS technologies into its Healthcare from the Eye initiative and further empower clinical decision-making using artificial intelligence (AI), especially for patients with diabetic retinopathy and other diabetic eye disease.

Topcon’s Healthcare from the Eye program is designed to facilitate directional care coordination between primary care providers (PCPs) and eye care providers (ECPs). The IRIS acquisition supports the company’s vision of a connected care model, allowing for early identification of patients at risk of ocular disease during PCP appointments. Following primary care visits, at-risk patients can be quickly referred to ECPs; using AI-analysed ocular data, optometrists and ophthalmologists can screen for signs of systemic or neurological disease and, if necessary, refer patients back to primary care for further evaluation.

Topcon also said the IRIS integration will strengthen its cloud-based connected care platform Harmony. Harmony is “designed to unify imaging, clinical insights and AI analytics across care settings,” the company said. Following the acquisition, Harmony will users will be able to access referral and communication capabilities of the IRIS platform. Topcon said the pairing will support infrastructure for robust shared clinical decision-making and improve patient compliance.

The IRIS platform is a camera-agnostic, cloud-based model for AI-assisted diabetic retinopathy screening. Founded in 2012, IRIS has enabled more than 1.8 million screenings and identified over 279,000 cases of diabetic retinopathy throughout more than 650 healthcare organisations, according to the press release. The IRIS mission is to improve quality scores and address gaps in the continuum of care. Its platform is used in routine clinical settings, Federally Qualified Health Centers and larger health systems; seamless EMR integration and broad camera compatibility maximise its scalability for providers in different environments.

Jacques Gilbert, Chief Strategy and Business Development Officer at Topcon Healthcare, Inc., commented on the news. “This acquisition reflects our long-term strategy to connect the continuum of care through intelligent platforms that bring together data, workflow, and real-time decision support,” Gilbert said. “IRIS enables us to expand the reach of the Healthcare from the Eye™ initiative into primary care, strengthening coordination between PCPs and ECPs, and ensuring patients receive timely, targeted care.”

Steven Martin, CEO at IRIS, also spoke about the ways in which the acquisition will allow his company to scale up and help more clinicians. “With Topcon Healthcare’s investment in connected care infrastructure, we’re well-positioned to expand our impact. Together, we’ll ensure providers of all sizes can confidently deliver preventive screenings that improve outcomes and reduce disparities,” Martin said.

Reference

  1. Topcon Healthcare Acquires Intelligent Retinal Imaging Systems to Enhance Connected Care Across Primary and Eye Care. Press release. Topcon Healthcare, Inc. Published July 30, 2025. Accessed July 30, 2025. https://topconhealthcare.com/article/topcon-healthcare-acquires-intelligent-retinal-imaging-systems-to-enhance-connected-care-across-primary-and-eye-care/

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.